Characterization of the Endothelin Receptor Subtypes in Human Prostate
Endothelin (ET) receptor subtypes in human prostate with benign prostatic hyperplasia were investigated by binding and functional studies. In the displacement experiment, LU224332 [endothelin-A/-B (ETA/ETB) nonselective antagonist] competed for [I]ET-1 binding with a monophasic curve. On the other h...
Gespeichert in:
| Veröffentlicht in: | Journal of cardiovascular pharmacology 2000, Vol.36 Suppl 1 (5 Suppl 1), p.S252-S254 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S254 |
|---|---|
| container_issue | 5 Suppl 1 |
| container_start_page | S252 |
| container_title | Journal of cardiovascular pharmacology |
| container_volume | 36 Suppl 1 |
| creator | Hiraoka, Yasuko Oshita, Masafumi Morikawa, Kouji Nagata, Osamu Hahn, Klaus J Hahn, Alfred Okada, Kenichiro Taniguchi, Takanobu Muramatsu, Ikunobu |
| description | Endothelin (ET) receptor subtypes in human prostate with benign prostatic hyperplasia were investigated by binding and functional studies. In the displacement experiment, LU224332 [endothelin-A/-B (ETA/ETB) nonselective antagonist] competed for [I]ET-1 binding with a monophasic curve. On the other hand, LU135252 (ETA-selective antagonist) and sarafotoxin S6c (S6c, ETB-selective agonist) competed for [I]ET-1 binding with shallow and biphasic curves. The analysis of the displacement curves for LU135252 and S6c showed that both ETA and ETB subtypes coexist but that ETA is the dominantly expressed receptor. In human prostate strips, 10 μM of both LU135252 and LU224332 strongly inhibited the contractile response to ET-1 with equal potency. However, 10 μM of BQ788 (ETB-selective antagonist) did not show a clear inhibition. S6c also produced a contractile response, which was potently inhibited by LU224332 or BQ788, and slightly suppressed by LU135252. These results suggest that in human prostate both ETA and ETB subtypes are functional receptors mediating contraction, but that ET-1-mediated contractions are predominantly mediated by activation of dominant receptor subtype, ETA |
| doi_str_mv | 10.1097/00005344-200036051-00074 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72404873</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72404873</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3384-b63ff8b2aab5b3b489315e761673bef00906d7e7aabe6425f537467f10096023</originalsourceid><addsrcrecordid>eNpdkU1PwzAMhiMEYmPwF1BP3ApOkybtEU2DIU0Cwe5R2jlqoR8jSTWNX09gBSRyea34tZ08JiSicE0hlzcQTso4j5MQMAEpjUMg-RGZ0pSxmEPCjskUqIA44VxMyJlzrwCUp1KckgmlIDOWw5TczSttdenR1h_a130X9SbyFUaLbtMHbeouesYSt7630ctQ-P0WXRQul0Oru-jJ9s5rj-fkxOjG4cWoM7K-W6zny3j1eP8wv13FJWMZjwvBjMmKROsiLVjBs5zRFKWgQrICDUAOYiNRhjwKnqQmZZILaWjIiPCnGbk6tN3a_n1A51VbuxKbRnfYD07JhAPPJAvG7GAswwOdRaO2tm613SsK6guh-kGofhGqb4Sh9HKcMRQtbv4KR2bBwA-GXd8Ebu6tGXZoVYW68ZX6vxoYV8M-Afteeq0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72404873</pqid></control><display><type>article</type><title>Characterization of the Endothelin Receptor Subtypes in Human Prostate</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Hiraoka, Yasuko ; Oshita, Masafumi ; Morikawa, Kouji ; Nagata, Osamu ; Hahn, Klaus J ; Hahn, Alfred ; Okada, Kenichiro ; Taniguchi, Takanobu ; Muramatsu, Ikunobu</creator><creatorcontrib>Hiraoka, Yasuko ; Oshita, Masafumi ; Morikawa, Kouji ; Nagata, Osamu ; Hahn, Klaus J ; Hahn, Alfred ; Okada, Kenichiro ; Taniguchi, Takanobu ; Muramatsu, Ikunobu</creatorcontrib><description>Endothelin (ET) receptor subtypes in human prostate with benign prostatic hyperplasia were investigated by binding and functional studies. In the displacement experiment, LU224332 [endothelin-A/-B (ETA/ETB) nonselective antagonist] competed for [I]ET-1 binding with a monophasic curve. On the other hand, LU135252 (ETA-selective antagonist) and sarafotoxin S6c (S6c, ETB-selective agonist) competed for [I]ET-1 binding with shallow and biphasic curves. The analysis of the displacement curves for LU135252 and S6c showed that both ETA and ETB subtypes coexist but that ETA is the dominantly expressed receptor. In human prostate strips, 10 μM of both LU135252 and LU224332 strongly inhibited the contractile response to ET-1 with equal potency. However, 10 μM of BQ788 (ETB-selective antagonist) did not show a clear inhibition. S6c also produced a contractile response, which was potently inhibited by LU224332 or BQ788, and slightly suppressed by LU135252. These results suggest that in human prostate both ETA and ETB subtypes are functional receptors mediating contraction, but that ET-1-mediated contractions are predominantly mediated by activation of dominant receptor subtype, ETA</description><identifier>ISSN: 0160-2446</identifier><identifier>EISSN: 1533-4023</identifier><identifier>DOI: 10.1097/00005344-200036051-00074</identifier><identifier>PMID: 11078390</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins, Inc</publisher><subject>Aged ; Aged, 80 and over ; Endothelin-1 - pharmacology ; Humans ; Male ; Middle Aged ; Norepinephrine - pharmacology ; Propionates - pharmacology ; Prostate - chemistry ; Prostate - drug effects ; Prostate - physiology ; Pyrimidines - pharmacology ; Radioligand Assay ; Receptor, Endothelin A ; Receptor, Endothelin B ; Receptors, Endothelin - analysis ; Receptors, Endothelin - physiology ; Viper Venoms - pharmacology</subject><ispartof>Journal of cardiovascular pharmacology, 2000, Vol.36 Suppl 1 (5 Suppl 1), p.S252-S254</ispartof><rights>2000 Lippincott Williams & Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3384-b63ff8b2aab5b3b489315e761673bef00906d7e7aabe6425f537467f10096023</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00005344-200036001-00074$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,776,780,4010,4595,27900,27901,27902,65434</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11078390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hiraoka, Yasuko</creatorcontrib><creatorcontrib>Oshita, Masafumi</creatorcontrib><creatorcontrib>Morikawa, Kouji</creatorcontrib><creatorcontrib>Nagata, Osamu</creatorcontrib><creatorcontrib>Hahn, Klaus J</creatorcontrib><creatorcontrib>Hahn, Alfred</creatorcontrib><creatorcontrib>Okada, Kenichiro</creatorcontrib><creatorcontrib>Taniguchi, Takanobu</creatorcontrib><creatorcontrib>Muramatsu, Ikunobu</creatorcontrib><title>Characterization of the Endothelin Receptor Subtypes in Human Prostate</title><title>Journal of cardiovascular pharmacology</title><addtitle>J Cardiovasc Pharmacol</addtitle><description>Endothelin (ET) receptor subtypes in human prostate with benign prostatic hyperplasia were investigated by binding and functional studies. In the displacement experiment, LU224332 [endothelin-A/-B (ETA/ETB) nonselective antagonist] competed for [I]ET-1 binding with a monophasic curve. On the other hand, LU135252 (ETA-selective antagonist) and sarafotoxin S6c (S6c, ETB-selective agonist) competed for [I]ET-1 binding with shallow and biphasic curves. The analysis of the displacement curves for LU135252 and S6c showed that both ETA and ETB subtypes coexist but that ETA is the dominantly expressed receptor. In human prostate strips, 10 μM of both LU135252 and LU224332 strongly inhibited the contractile response to ET-1 with equal potency. However, 10 μM of BQ788 (ETB-selective antagonist) did not show a clear inhibition. S6c also produced a contractile response, which was potently inhibited by LU224332 or BQ788, and slightly suppressed by LU135252. These results suggest that in human prostate both ETA and ETB subtypes are functional receptors mediating contraction, but that ET-1-mediated contractions are predominantly mediated by activation of dominant receptor subtype, ETA</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Endothelin-1 - pharmacology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Norepinephrine - pharmacology</subject><subject>Propionates - pharmacology</subject><subject>Prostate - chemistry</subject><subject>Prostate - drug effects</subject><subject>Prostate - physiology</subject><subject>Pyrimidines - pharmacology</subject><subject>Radioligand Assay</subject><subject>Receptor, Endothelin A</subject><subject>Receptor, Endothelin B</subject><subject>Receptors, Endothelin - analysis</subject><subject>Receptors, Endothelin - physiology</subject><subject>Viper Venoms - pharmacology</subject><issn>0160-2446</issn><issn>1533-4023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1PwzAMhiMEYmPwF1BP3ApOkybtEU2DIU0Cwe5R2jlqoR8jSTWNX09gBSRyea34tZ08JiSicE0hlzcQTso4j5MQMAEpjUMg-RGZ0pSxmEPCjskUqIA44VxMyJlzrwCUp1KckgmlIDOWw5TczSttdenR1h_a130X9SbyFUaLbtMHbeouesYSt7630ctQ-P0WXRQul0Oru-jJ9s5rj-fkxOjG4cWoM7K-W6zny3j1eP8wv13FJWMZjwvBjMmKROsiLVjBs5zRFKWgQrICDUAOYiNRhjwKnqQmZZILaWjIiPCnGbk6tN3a_n1A51VbuxKbRnfYD07JhAPPJAvG7GAswwOdRaO2tm613SsK6guh-kGofhGqb4Sh9HKcMRQtbv4KR2bBwA-GXd8Ebu6tGXZoVYW68ZX6vxoYV8M-Afteeq0</recordid><startdate>2000</startdate><enddate>2000</enddate><creator>Hiraoka, Yasuko</creator><creator>Oshita, Masafumi</creator><creator>Morikawa, Kouji</creator><creator>Nagata, Osamu</creator><creator>Hahn, Klaus J</creator><creator>Hahn, Alfred</creator><creator>Okada, Kenichiro</creator><creator>Taniguchi, Takanobu</creator><creator>Muramatsu, Ikunobu</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2000</creationdate><title>Characterization of the Endothelin Receptor Subtypes in Human Prostate</title><author>Hiraoka, Yasuko ; Oshita, Masafumi ; Morikawa, Kouji ; Nagata, Osamu ; Hahn, Klaus J ; Hahn, Alfred ; Okada, Kenichiro ; Taniguchi, Takanobu ; Muramatsu, Ikunobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3384-b63ff8b2aab5b3b489315e761673bef00906d7e7aabe6425f537467f10096023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Endothelin-1 - pharmacology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Norepinephrine - pharmacology</topic><topic>Propionates - pharmacology</topic><topic>Prostate - chemistry</topic><topic>Prostate - drug effects</topic><topic>Prostate - physiology</topic><topic>Pyrimidines - pharmacology</topic><topic>Radioligand Assay</topic><topic>Receptor, Endothelin A</topic><topic>Receptor, Endothelin B</topic><topic>Receptors, Endothelin - analysis</topic><topic>Receptors, Endothelin - physiology</topic><topic>Viper Venoms - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hiraoka, Yasuko</creatorcontrib><creatorcontrib>Oshita, Masafumi</creatorcontrib><creatorcontrib>Morikawa, Kouji</creatorcontrib><creatorcontrib>Nagata, Osamu</creatorcontrib><creatorcontrib>Hahn, Klaus J</creatorcontrib><creatorcontrib>Hahn, Alfred</creatorcontrib><creatorcontrib>Okada, Kenichiro</creatorcontrib><creatorcontrib>Taniguchi, Takanobu</creatorcontrib><creatorcontrib>Muramatsu, Ikunobu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiovascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hiraoka, Yasuko</au><au>Oshita, Masafumi</au><au>Morikawa, Kouji</au><au>Nagata, Osamu</au><au>Hahn, Klaus J</au><au>Hahn, Alfred</au><au>Okada, Kenichiro</au><au>Taniguchi, Takanobu</au><au>Muramatsu, Ikunobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of the Endothelin Receptor Subtypes in Human Prostate</atitle><jtitle>Journal of cardiovascular pharmacology</jtitle><addtitle>J Cardiovasc Pharmacol</addtitle><date>2000</date><risdate>2000</risdate><volume>36 Suppl 1</volume><issue>5 Suppl 1</issue><spage>S252</spage><epage>S254</epage><pages>S252-S254</pages><issn>0160-2446</issn><eissn>1533-4023</eissn><abstract>Endothelin (ET) receptor subtypes in human prostate with benign prostatic hyperplasia were investigated by binding and functional studies. In the displacement experiment, LU224332 [endothelin-A/-B (ETA/ETB) nonselective antagonist] competed for [I]ET-1 binding with a monophasic curve. On the other hand, LU135252 (ETA-selective antagonist) and sarafotoxin S6c (S6c, ETB-selective agonist) competed for [I]ET-1 binding with shallow and biphasic curves. The analysis of the displacement curves for LU135252 and S6c showed that both ETA and ETB subtypes coexist but that ETA is the dominantly expressed receptor. In human prostate strips, 10 μM of both LU135252 and LU224332 strongly inhibited the contractile response to ET-1 with equal potency. However, 10 μM of BQ788 (ETB-selective antagonist) did not show a clear inhibition. S6c also produced a contractile response, which was potently inhibited by LU224332 or BQ788, and slightly suppressed by LU135252. These results suggest that in human prostate both ETA and ETB subtypes are functional receptors mediating contraction, but that ET-1-mediated contractions are predominantly mediated by activation of dominant receptor subtype, ETA</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>11078390</pmid><doi>10.1097/00005344-200036051-00074</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0160-2446 |
| ispartof | Journal of cardiovascular pharmacology, 2000, Vol.36 Suppl 1 (5 Suppl 1), p.S252-S254 |
| issn | 0160-2446 1533-4023 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72404873 |
| source | MEDLINE; Journals@Ovid LWW Legacy Archive; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Aged Aged, 80 and over Endothelin-1 - pharmacology Humans Male Middle Aged Norepinephrine - pharmacology Propionates - pharmacology Prostate - chemistry Prostate - drug effects Prostate - physiology Pyrimidines - pharmacology Radioligand Assay Receptor, Endothelin A Receptor, Endothelin B Receptors, Endothelin - analysis Receptors, Endothelin - physiology Viper Venoms - pharmacology |
| title | Characterization of the Endothelin Receptor Subtypes in Human Prostate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T00%3A04%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20the%20Endothelin%20Receptor%20Subtypes%20in%20Human%20Prostate&rft.jtitle=Journal%20of%20cardiovascular%20pharmacology&rft.au=Hiraoka,%20Yasuko&rft.date=2000&rft.volume=36%20Suppl%201&rft.issue=5%20Suppl%201&rft.spage=S252&rft.epage=S254&rft.pages=S252-S254&rft.issn=0160-2446&rft.eissn=1533-4023&rft_id=info:doi/10.1097/00005344-200036051-00074&rft_dat=%3Cproquest_cross%3E72404873%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72404873&rft_id=info:pmid/11078390&rfr_iscdi=true |